This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
zacks-consensus-estimate: Archive
Why Is Gitlab (GTLB) Up 1.9% Since Last Earnings Report?
by Zacks Equity Research
Gitlab (GTLB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GTLBPositive Net Change SNOWNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Why Is Dollar General (DG) Up 9.6% Since Last Earnings Report?
by Zacks Equity Research
Dollar General (DG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DGPositive Net Change TGTNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Why Is Ulta (ULTA) Down 3.5% Since Last Earnings Report?
by Zacks Equity Research
Ulta (ULTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ULTAPositive Net Change BBWINegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Signet (SIG) Down 0.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Signet (SIG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SIGNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Palo Alto (PANW) Up 25.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Palo Alto (PANW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PANWNegative Net Change SNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Victoria's Secret (VSXY) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Victoria's Secret (VSXY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
VSXYNegative Net Change CPRIPositive Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
PepsiCo (PEP) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
PepsiCo (PEP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PEPPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts Believe Daktronics (DAKT) Could Rally 54.28%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 54.3% upside potential for Daktronics (DAKT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
DAKTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Progress Software (PRGS) Could Rally 26.84%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.8% in Progress Software (PRGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PRGSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
LYELPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate